Compare Citius Pharmaceuticals Inc (CTXR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gilead Sciences, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 13392.1× Citius Pharmaceuticals Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Gilead Sciences, Inc. for 111 Days on average.
| CTXR | GILD | |
|---|---|---|
Market Cap | $13.62M | $182.40B |
Volume | 132,438 | 4,469,821 |
Sector | Health | Health |
52-Week High | $1.82 | $155.80 |
52-Week Low | $0.48 | $117.18 |
Typical Hold Time | 17 Days | 111 Days |
Enterprise Value | $3.79M | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
